mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate efficacity and safety of everolimus or (cyclosporine then
everolimus) vs. cyclosporine as immunosuppressive treatment in renal transplantation for
elderly (>60 years old) recipients receiving graft from elderly donor(>60 years old).
Phase:
Phase 3
Details
Lead Sponsor:
University Hospital, Brest
Collaborators:
Genzyme, a Sanofi Company Ministry of Health, France Novartis Roche Pharma AG